Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 7/20 | 0.42 |
| ▸ | FABP7 | O15540 | 2/20 | 0.39 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | ACE | P12821 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9878033 | 0.88 | FKBP1A (0.49) | FKBP1AKMT2AACEMEN1CYP3A4 | |
| SCHEMBL9877388 | 0.88 | FKBP1A (0.49) | FKBP1AKMT2AACEMEN1CYP3A4 | |
| SCHEMBL17356388 | 0.87 | ACE (0.45) | FABP7FABP5KMT2AACEMEN1 | |
| SCHEMBL22648502 | 0.87 | ACE (0.45) | FABP7FABP5KMT2AACEMEN1 | |
| SCHEMBL29634854 | 0.87 | ACE (0.45) | FABP7FABP5KMT2AACEMEN1 | |
| SCHEMBL28777376 | 0.87 | ACE (0.45) | FABP7FABP5KMT2AACEMEN1 | |
| SCHEMBL3308417 | 0.87 | ACE (0.45) | FABP7FABP5KMT2AACEMEN1 | |
| SCHEMBL4799791 | 0.85 | ACE (0.42) | FABP7FABP5KMT2AACEMEN1 | |
| SCHEMBL3311702 | 0.85 | FABP5 (0.36) | FKBP1AFABP7FABP5KMT2AACE | |
| SCHEMBL4802204 | 0.85 | ACE (0.45) | FABP7FABP5KMT2AACEMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125695-B1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX SCIENCE IRELAND (IE) | 2016-10-26 | — | — | EP | disclosed |
| US-20100099729-A1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX S.A. (FR) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099729-A1 | NITRIC OXIDE DONOR COMPOUNDS | NOS3, NOS2, NOS1 | FKBP1A 3368/4885FABP7 2520/4885FABP5 3689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.